New drug Kylo-11 targets hidden heart risk in early human test
Disease control
Completed
This early-stage study tested a single dose of Kylo-11 in 71 healthy adults with high levels of Lp(a), a protein linked to heart disease. The main goal was to check safety and how the drug moves through the body. Researchers also looked at whether Kylo-11 could lower Lp(a) levels…
Phase: PHASE1 • Sponsor: Kylonova (Xiamen) Biopharma co., LTD. • Aim: Disease control
Last updated May 17, 2026 11:23 UTC